Search

Your search keyword '"Cibula, David"' showing total 621 results

Search Constraints

Start Over You searched for: Author "Cibula, David" Remove constraint Author: "Cibula, David" Language english Remove constraint Language: english
621 results on '"Cibula, David"'

Search Results

3. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations

4. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors

5. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

6. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas

7. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

8. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer

9. Microsatellite instability in non-endometrioid ovarian epithelial tumors: a study of 400 cases comparing immunohistochemistry, PCR, and NGS based testing with mutation status of MMR genes

10. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance

12. Role of adjuvant therapy in intermediate-risk cervical cancer patients – Subanalyses of the SCCAN study

13. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories

18. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples

19. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

22. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

23. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

24. Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial – SENTIX

25. Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study

26. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial

28. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

29. Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome

30. Direct mailing of HPV self-sampling kits to women aged 50-65 non-participating in cervical screening in the Czech Republic.

32. Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial.

33. The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023).

37. SUCCOR cone study: conization before radical hysterectomy

38. Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer

39. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study

44. Response to: Correspondence on 'ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors' by Thomassin-Nagarra et al

45. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

46. Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative—GO SOAR)

47. Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators

49. The genetic landscape of 87 ovarian germ cell tumors

50. Sonographic, Demographic, and Clinical Characteristics of Pre- and Postmenopausal Women with Endometrial Cancer; Results from a Post Hoc Analysis of the IETA4 (International Endometrial Tumor Analysis) Multicenter Cohort.

Catalog

Books, media, physical & digital resources